Diagnostic Value of Tc-99mMDP Bone Scan in Assessment of Renal Functions in Cancer Patients Compared to Estimated Glomerular Filtration Rate.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-01

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

-To compare the glomerular filtration rate obtained by Tc-99mMDP through Gate's method to estimated glomerular filtration rate (eGFR) and assess if we can do metastatic work up and evaluate renal function at a single Tc-99mMDP study, thereby reducing cost, time and radiation exposure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

68Ga-PSMA PET/CT for Ra223 Assessment

NCT04951817

Metastatic Prostate Cancer

RECRUITING NA

Two Bed SPECT/CT Versus Planar Bone Scintigraphy in Detection of Osseous Metastases in Patients With Genitourinary Malignancies

NCT05597215

Bone Metastases Urogenital Cancer

UNKNOWN

A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging

NCT06769893

RCC, Renal Cell Cancer

RECRUITING NA

Advanced Diffusion Imaging in Renal Cancer Patients

NCT06116253

Renal Cancer

RECRUITING NA

Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer

NCT04481230

Osteoarthritis, Knee Breast Cancer

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Bone scan is one of the frequently used imaging tests in nuclear medicine. It is applied as a test for some oncologic and non-oncologic diseases; the common use is for the detection of bone metastasis from malignant tumors. Renal function may worsen with increasing age, co-morbidities like diabetes, hypertension, acute loss of weight and muscle mass, dehydration and long term use of non-steroidal inflammatory drugs and after some malignancies like multiple myeloma. Therefore renal function assessment is important and can be done by glomerular filtration rate using dGFR. Such a method uses technetium-99m-diethyl-triamine-penta-acetic acid (99mTc-DTPA). Other methods are SCR levels and estimated glomerular filtration rate (eGFR). The use of nephrotoxic drugs such as cisplatin is one of the chemotherapeutic agents in the treatment of a variety of solid tumors; however, it has a side effect of nephrotoxicity. In addition, methotrexate is primarily excreted by the kidneys and estimate of renal function is essential before the use of high-dose therapy.
* Glomerular filtration rate indicates creatinine clearance (CrCl), i.e., a ratio of the concentration of creatinine in serum and urine. Serum creatinine and CrCl have the leading role in the early diagnosis, monitoring and classification of chronic renal insufficiency. MDRD equation may be used for the estimation of glomerular filtration rate, which is accepted due to its simplicity, economic viability and acceptable performance. The most commonly used formula is the "4-varibale MDRD," which estimates GFR using four variables: Serum creatinine, age, race and gender.
* Information about the kidneys can be obtained from bone scan because Tc-99mMDP is excreted through the kidneys. Tc-99mMDP can be an alternative to Tc-99mDTPA for evaluating renal function while conducting bone metastases surveys in patients with urinary tract malignancy with reduced cost and radiation exposure.
* The study aims to investigate the use of Tc-99mMDP for assessing glomerular filtration rate to assess metastatic work up and renal function at a single Tc-99mMDP study, thereby reducing cost, time and radiation exposure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Patients Treated by Nephrotoxic Chemotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tc-99mMDP bone scan

5 mCi of Tc-99mMDP is used for dynamic renography followed by 15 mCi for post 3-hr whole body imaging.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients with a known history of malignancy treated by nephrotoxic chemotherapy as Cisplatin, who are referred to do bone scan as a part of the metastatic workup. These patients must have recent renal function including serum creatinine, in order to calculate estimated glomerular filtration rate (eGFR) (no chemotherapy is given after the recorded renal function). History of renal problems, previous surgery or medical treatment for the kidney will be reported. Type, duration and dose of chemotherapy also will be reported.

Exclusion Criteria

* Patients with known renal failure,Patients refuse to do the scan,Patients with relative or absolute contraindications to do the scan (eg. pregnancy).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No